Genelux Corporation GNLX
Set alert
1.96 USD -0.04 -2.00%
As of Nov 3, 10:57 AM ET
1.97 Day range 2.06
1.86 52-week range 8.54
- YTD
- -55.05%
- 1 year
- -76.21%
- Open
- 2.01
- Prev close
- 2.00
- Mkt cap
- 89.13M
- Vol
- 91.60K
- Avg vol
- 358.64K
- EPS
- -0.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.97
- High
- 2.06
- Forward P/E
- -2.45
- Beta
- 0.00
- Short ratio
- 8.90
- Inst. own
- 15.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 2.72
- 200-d avg
- 3.02
- 1y target
- 18.40
1D chart
Signals (32)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | 1:38 PM | 21 hours ago |
| MACD: Buy Signal | 1:23 PM | 21 hours ago |
| MACD: Sell Signal | 1:15 PM | 21 hours ago |
| MACD: Buy Signal | 1:11 PM | 21 hours ago |
| RSI: Oversold | 1:05 PM | 21 hours ago |
| MACD: Sell Signal | 12:52 PM | 22 hours ago |
| MACD: Buy Signal | 12:50 PM | 22 hours ago |
| MACD: Sell Signal | 12:46 PM | 22 hours ago |
| RSI: Overbought | 12:39 PM | 22 hours ago |
| MACD: Buy Signal | 12:17 PM | 22 hours ago |
| SMA: Bearish | 12:08 PM | 22 hours ago |
| RSI: Oversold | 12:08 PM | 22 hours ago |
| MACD: Sell Signal | 11:58 AM | 23 hours ago |
| MACD: Buy Signal | 11:52 AM | 23 hours ago |
| SMA: Bullish | 11:50 AM | 23 hours ago |
| SMA: Bullish | 11:50 AM | 23 hours ago |
| SMA: Bearish | 11:49 AM | 23 hours ago |
| SMA: Bearish | 11:49 AM | 23 hours ago |
| MACD: Sell Signal | 11:49 AM | 23 hours ago |
| SMA: Bullish | 11:37 AM | 23 hours ago |
Newest 20 of 32.
Key statistics
- Market cap
- 79.44M
- Enterprise value
- 49.05M
- Trailing P/E
- 0.00
- Forward P/E
- -2.45
- PEG ratio
- 0.00
- Price / sales
- 9929.73
- Price / book
- 3.11
- EPS (TTM)
- -0.94
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 8.00K
- Revenue growth
- 0.00%
- Free cash flow
- -11.90M
- Total cash
- 33.64M
- Total debt
- 2.21M
- Return on equity
- -88.57%
- Shares outstanding
- 34.54M
- Short % of float
- 4.92%
- 50-day average
- 2.72
- 200-day average
- 3.02
Analyst view
Consensus: none
Price target (mean) 18.40 +838.8% upside
Now 1.96
- Target (low)
- 8.00
- Target (mean)
- 18.40
- Target (high)
- 30.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.1925.
Financials — quick view
GNLX Revenue — quarterly 0
GNLX Net income — quarterly -9.47M
GNLX EPS — quarterly -0.21
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.19 | -0.19 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| Mar 29, 2024 | Dec 1, 2023 | -0.21 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -0.21 | -0.25 | -0.04 | -19.05% |
| Nov 14, 2023 | Sep 1, 2023 | -0.12 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 29, 2024 | Guggenheim | init | — | Buy |
| Aug 27, 2024 | Roth MKM | init | — | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 3, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| May 31, 2024 | Benchmark | main | Speculative Buy | Speculative Buy |
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- genelux.com
News
- Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate
- Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- Genelux (GNLX) Projected to Post Quarterly Earnings on Thursday
- Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In Heavily Pretreated Patients With Platinum-R/R Ovarian Cancer
- Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
Your note
Sign in to keep a note on GNLX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAPPELLO JOSEPH | Officer | Stock Award(Grant) | Dec 17, 2024 | 43,653 |
| MIRABELLI MARY | Director | Stock Award(Grant) | Jul 31, 2024 | 52,001 |
| RYDER SEAN | General Counsel | Stock Award(Grant) | Dec 17, 2024 | 41,388 |
| SMALLING RALPH | Officer | Stock Award(Grant) | Dec 17, 2024 | 31,847 |
| SMITHER JOHN W | Director | Stock Award(Grant) | Jul 31, 2024 | 52,711 |
| SZALAY ALADAR | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 12, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 3.89% | 1,343,363 | 3.09M | Sep 29, 2024 |
| Vanguard Group Inc | 2.85% | 984,851 | 2.27M | Sep 29, 2024 |
| Millennium Management Llc | 1.06% | 364,929 | 839.34K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.92% | 316,160 | 727.17K | Sep 29, 2024 |
| Blackrock Inc. | 0.90% | 310,287 | 713.66K | Sep 29, 2024 |
| Bank of America Corporation | 0.63% | 216,781 | 498.60K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.97% | 679,800 | 1.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.82% | 284,119 | 653.47K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 158,398 | 364.31K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.26% | 90,651 | 208.50K | Aug 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 61,763 | 142.05K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 51,780 | 119.09K | Oct 30, 2024 |